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ABSTRACT
Objective: The objective of the study was to compare the incidence of acute graft versus host disease (aGVHD) between oral and intravenous (IV) 
initial standard cyclosporine A (CsA) prophylaxis in a tertiary care center in Mexico.
Methods: A total of 117 consecutive patients who underwent allogeneic hematopoietic stem cell transplantations (HSCT) were retrospectively 
analyzed. GVHD prophylaxis consisted of CsA and methotrexate (MTX). CsA was administered IV, until 2005, when it was withdrawn from the market, 
and CsA was administered orally.
Results: Most of the patients were male (55%), with a median age of 33 years (range, 15–63). 92 patients (79%) received CsA orally, and 25 (22%) 
intravenously. There were no significant differences in CsA concentrations during weeks 1, 2, 3, and 4 between the oral and IV group. From the entire 
cohort, 1 patient (4%) from the IV group and 16 (17%) from the oral group developed aGVHD, respectively. Sex, gender disparity, and HSCT source 
were statistically associated with aGVHD in the multivariate analysis. 
Conclusions: Using oral instead of IV CsA for aGVHD prophylaxis is feasible and could be financially efficient; nonetheless, our results showed a higher 
incidence of aGVHD in the oral group; however, our study has limitations and further prospective studies including a larger cohort are encouraged.
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INTRODUCTION
Acute graft versus host disease (aGVHD) can affect 20–60% of 
patients undergoing myeloablative allogeneic hematopoietic stem cell 
transplantations (allo-HSCT), and up to 50% can develop clinically 
significant grades (˃II). Using reduced-intensity conditioning regimens 
can lower the incidence; nonetheless, severe aGVHD in this context still 
occurs in up to 20%. Due to its potent immunosuppressive activity, 
cyclosporine A (CsA) has been administered for GVHD prophylaxis 
since 1978 and the combination with methotrexate (MTX) is the most 
widely used regimen. CsA can be administered orally or intravenously, 
but some factors can influence oral cyclosporine bioavailability. Usually, 
initial dosing is administered intravenously during the 1st month post-
allo-HSCT, and changed to oral when the patient is discharged. On 
the other hand, cyclosporine dosage usually begins at a higher dose 
(loading dose), with a gradual taper over time. However, administration, 
measuring, and dosing schedules of CsA vary between centers [1,2]. 
Moreover, it is important to maintain high concentration levels of CsA 
within the 1st weeks after allo-HSCT, since low concentrations increase 
the risk of acute GVHD development [3,4].
To date, there is not enough information regarding the use of oral versus 
intravenous (IV) CsA as initial dose for prophylaxis of aGVHD [5,6]. At 
the beginning of our transplantation program, intravenous (IV) CsA 
was administered during the inpatient period, but this formulation was 
discontinued in our country in 2005 making mandatory to use oral CsA 
instead. Our objective was to compare aGVHD incidence between oral 
and IV initial CsA standard prophylaxis during the 1st-month post-allo-
HSCT in a referral/tertiary care center in Mexico.
seventeen total of 117 consecutive patients who underwent allo-HSCT 
from January 2000 to 2017, and received CsA as immunosuppressive 
prophylaxis at the National Institute of Medical Sciences and Nutrition 
Salvador Zubiran in Mexico City, were retrospectively analyzed. 
The dataset used for this study derived from patients’ information 
collected from the Transplantation Program records, containing all 
the information of the transplant procedure. Furthermore, hospital 
electronic and imaging records were revised. Patient data were de-
identified, and to the retrospective nature of this study, our Institutional 
Review Board approved the usage of patients’ information without 
informed consent.
All patients received conditioning regimens and remained hospitalized 
until hematological and clinical recovery. The following myeloablative 
conditioning regimens were used: (1) Reduced BUCY, (2): Busulfan 
12 mg/kg, divided in 4 days (3 mg/kg/day, ORAL, during days -7, -6, -5, 
and -4) and cyclophosphamide (Cy), IV, 80 mg/kg, divided in 2 days 
(40 mg/kg/day, during days -3, and -2), and (3) BUCY 2: Busulfan 16 mg/
kg, and Cy 120 mg/kg. Non-myeloablative regimens included: (1) Cy 
50 mg/kg divided in 4 days, (2) Cy 50 mg/kg divided in 4 days, and ATG 
30 mg/kg divided in 3 days, and (3) Fludarabine 30 mg/msq for 5 days, Cy 
50 mg/kg/day divided in 4 days, and ATG 10 mg/kg/day divided in 4 days.
GVHD prophylaxis consisted of CsA and MTX. CsA was administered 
IV, (1.5 mg/kg/12 h, during day-1 and adjusted to serum levels 
(200–300 μg/mL)); in 2005, CsA was administered orally (10 
mg/kg during day-1, and 5 mg/kg starting day 0, adjusting according to 
therapeutic monitoring) as the IV formulation was withdrawn from the 
market. MTX was administered IV (10 mg/m2/day on days +3, +6, +11).
CsA concentration was daily measured before the administration of next 
dose, until the patient was discharged to maintain target concentrations 
of 200–300 μg/mL. Acute and chronic GVHD was graded around the 
time of diagnosis according to the established NIH criteria [7].
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Patients were dichotomized according to the route of administration 
of CsA. Continuous variables were described by the median and 
interquartile range using the frequency analysis. Categorical variables 
were described by frequencies and percentiles. Variables with normal 
distribution were compared with independent t-test or one-way 
ANOVA. Categorical variables were compared with the Chi-square 
or Fisher’s exact test. Cox regression analysis was used to examine 
variables affecting aGVHD incidence. Logistic regression was used to 
correlate CsA concentrations with GVHD incidence. The probability 
of developing acute GVHD was depicted by calculating the cumulative 
incidence as competing risks. Two-sided p<0.05 was considered 
significant. SPSS v.21 (IBM, Chicago, IL) was used.
A total of 117 consecutive patients were included. Most of the patients 
were male (55%), with a median age of 33 years (range, 15-63). 
92 patients (79%) received CsA orally, and 25 (22%) intravenously. 
Patients’ characteristics are shown in Table 1, demonstrating statistically 
significant differences between both groups (oral vs. IV) exclusively in 
the HSCT source (BM 73% vs. 92%). Mean blood concentrations of CsA 
are also described in Table 1, showing that there were no significant 
differences in CsA concentrations during weeks 1, 2, 3, and 4 between 
the oral and IV group: p=0.5, 0.8, 0.3, and 0.8, respectively. Most of 
the patients received myeloablative conditioning regimens: Reduced 
BUCY 2 (n=83, 71%) and BUCY 2 (n=2, 2%). From the entire cohort, 
17 patients (15%) developed acute GVHD (Grade I in 1, Grade II in 8, 
Table 1: Patient and HSCT characteristics
Characteristic Oral CsA n (%/range) 
n=92
IV CsA n (%/range) 
n=25




Male 50 (54) 14 (56) 64 (55) 0.8
Female 42 (46) 11 (44) 53 (45)
Age (Years)
˂20 12 (13) 0 (0) 12 (10) 0.2
20–40 53 (58) 15 (60) 68 (58)
˃40 27 (29) 10 (40) 37 (32)
Disease
AA 16 (17) 7 (28) 23 (19) 0.5
ALL 23 (25) 1 (4) 24 (21)
MDS 14 (15) 4 (16) 18 (15)
CML 6 (6.5) 8 (32) 14 (12)
AML 14 (15) 3 (12) 17 (15)
Lymphomas 5 (5.5) 2 (8) 7 (6)
Others 13 (16) 0 (0) 13 (12)
CMV status
Recipient +/donor+ 44 (48) 15 (60) 59 (50) 0.2
Recipient +/donor− 6 (7) 4 (16) 10 (9)
Recipient −/donor+ 8 (9) 2 (8) 10 (9)
Recipient −/donor− 7 (8) 1 (4) 8 (7)
Unknown 27 (28) 3 (12) 30 (26)
HLA status
Identical related donor 85 (92) 25 (100) 110 (94) 0.1
Matched unrelated donor 7 (8) 0 (0) 7 (6)
Gender disparity
No 48 (52) 17 (68) 65 (56) 0.2
Female receptor, male donor 22 (24) 4 (16) 26 (22)
Male receptor, female donor 18 (19) 4 (16) 22 (19)
Unknown 4 (5) 0 (0) 4 (3)
Conditioning regimen
Reduced BUCY2 68 (74) 15 (60) 83 (71) 0.1
BUCY2 1 (1) 1 (4) 2 (2)
ATG+Flu+CFM 6 (5) 5 (20) 11 (9)
ATG+CFM 9 (8) 0 (0) 9 (8)
ATG+Blu+Flu 2 (2) 0 (0) 2 (2)
Others 6 (6) 4 (16) 6 (5)
CD34+x (106/kg)
˂3 68 (74) 20 (80) 88 (75) 0.09
≥3 19 (21) 5 (20) 24 (20.5)
Unknown 5 (5) 0 (0) 5 (4.5)
HSCT source
Peripheral blood 22 (24) 2 (8) 24 (21) 0.02
Bone marrow 67 (73) 23 (92) 90 (77)
Cord blood 3 (3) 0 (0) 3 (3)
Engraftment (days)
Neutrophils 20 (11–40) 17 (7–43) Median: 20 (range, 7–43) 0.001
Platelets 15 (7–79) 15.5 (5–46) Median: 15 (range, 5–79) 0.7
Transfusions (units)
Red blood cells 2 (0–42) 3 (0–15) Median: 2 (range, 0–42) 0.2
Apheresis platelets 5 (1–51) 5.5 (0–25) Median: 5 (range, 0–51) 0.8
Hospitalization (days) 35 (19–112) 30.5 (12–128) Median: 34 (range, 12–128) 0.09
CSA concentration levels
Week 1 202 (44–609) 206 (108–539) Median: 202.5 (range, 44–609) 0.5
Week 2 223 (67–699) 229 (152–615) Median: 223.5 (range, 67–699) 0.8
Week 3 243 (76–1010) 271 (127–578) Median: 244 (range, 76–1010) 0.3
Week 4 239 (87–781) 233 (186–311) Median: 238 (range, 87–781) 0.8
HSCT: Hematopoietic stem cell transplantations, CSA: Cyclosporine A
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Grade III in 7, and Grade IV in 1), with a median onset of 40 days (range, 
12–89). One patient (4%) from the IV group, and 16 patients (17%) 
from the oral group; however, there was no significant association 
between the administration route and aGVHD incidence (p=0.09) 
(Fig. 1), or grading (p=0.2). Skin was the most affected site (n=13, 75%), 
followed by liver (n=10), and intestine (n=4).
Twenty eight patients (24%) developed chronic GVHD; 5 (20%) from 
the IV group, which was limited in all of them, and 23 (25%) from 
the oral group, which was limited in 74%, with a median onset of 
4.9 months (range, 3.3–45.3). No statistical association between the 
administration route and chronic GVHD incidence or grading was found 
(p=0.8 and 0.4, respectively).
Administration of ATG as part of the conditioning regimen (n=30, 
Table 1) showed a lower frequency of acute and chronic GVHD, 7% 
and 17%, respectively, compared to 17% and 27% in the myeloablative 
group, not showing statistically significance (p=0.2 for both groups); 
further, when excluding patients who received ATG as part of the 
conditioning regimen, no differences were observed between the 
administration route and the frequency of acute or chronic GVHD 
(p=0.3 and 0.5, respectively).
Clinical variables were associated with aGVHD in a univariate analysis, 
and only those with p value ˂0.05 were considered significant after the 
multivariate Cox regression. Sex, gender disparity, and HSCT source 
were statistically significant in the multivariate analysis (Table 2). No 
correlations were observed between CsA levels in week 1, 2, 3, or 4 and 
the occurrence of acute or chronic GVHD. Moreover, no correlations 
were observed excluding patients receiving ATG.
One of the main obstacles to broader application of allo-HSCT is GVHD. 
There are standards and guidelines for GVHD prophylaxis since once 
established, it can be difficult to treat and can potentially impair 
patient’s quality of life. Worldwide, prophylaxis in transplantations 
using myeloablative conditioning regimens consists in administering 
CsA with a short course of MTX [8] or mycophenolate mofetil. According 
to the EBMT, the initial route of administration of CsA is mostly IV [1]. 
From a practical standpoint, CsA is administered to achieve a therapeutic 
level, but beyond that, it is important to deliver the planned dose as per 
protocol. CsA pharmacokinetics may vary according to several factors, 
such as age, and there is no strong evidence to support applying a fixed 
conventional starting dose of CsA to every patient. We demonstrated 
that it is possible to maintain optimal mean concentrations of CsAusing 
both IV and oral administration during weeks 1–4, and no differences 
were observed.
We observed a low incidence of aGVHD in all the cohort (15%, 
6.8% Grades III–IV), compared to published literature [9], although 
more patients in the oral group presented aGVHD compared to 
IV administration (17% and 4%, respectively), it is important to 
highlight that since IV CsA was discontinued in our country in 2005, 
only 25 patients in our cohort received IV formulation, compared to 
92 patients receiving oral CsA, which could explain that despite the 
different percentages, no statistical significance was observed.
On the other hand, chronic GVHD was also lower (oral vs. IV, 24 vs. 
20%, respectively) when compared to the previously published 
literature [10], with similar survival compared to previously reported 
studies.
Table 2: Univariate and multivariate analysis of factors associated with acute GVHD
Univariate Multivariate (adjusted) Cox regression
Variable OR (CI 95%) p Variable OR (CI 95%) p
Sex Sex
Female 1.5 (0.6–3.8) 0.4 Female 3 (0.9–9.4) 0.05
Male 1 (Ref) Male 1 (Ref)
Age Age
≥40 0.8 (0.3–2.2) 0.7 ≥40 0.4 (0.1–1.3) 0.1
<40 1 (Ref) <40 1 (Ref)
HLA status HLA status
Matched unrelated donor 1.08 (0.1–6.6) 0.9 Matched unrelated donor - -
Identical related donor 1 (Ref) Identical related donor 1 (Ref)
Gender disparity Gender disparity
Yes 2.5 (1–6.3) 0.06 Yes 3.8 (1.1–13) 0.02
No 1 (Ref) No 1 (Ref)
HSC source HSC Source
Peripheral blood 3.7 (1.5–8.9) 0.005 Peripheral blood 4 (1.3–11.6) 0.01
Bone marrow 1 (Ref) Bone marrow 1 (Ref)
Conditioning regimen Conditioning regimen
Myeloablative 2.5 (0.6–10.6) 0.2 Myeloablative 1.5 (0.3–7.4) 0.5
Non-myeloablative 1 (Ref) Non-myeloablative 1 (Ref)
Cyclosporine Cyclosporine
Intravenous 0.2 (0.03–1.6) 0.1 Oral 0.3 (0.04–2.5) 0.2
Oral 1 (Ref) Intravenous 1 (Ref)
Ref: Reference; OR: Odds ratio; -: Not obtained. aGVHD: Graft versus host disease
Fig. 1: Cumulative incidence of acute graft versus host disease 
in patients receiving intravenous versus oral cyclosporine A 
(p=0.09)
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Further, the median age in our cohort was relatively low (68% 
≤40 years), a fact that could have contributed to our overall favorable 
results, along with 94% of patients having an HLA-identical sibling 
donor. Furthermore, the low incidence of aGVHD in both groups could 
have been related with the use of bone marrow as the source of the 
HSCT, along with the dosage reduction of our most frequently used 
myeloablative conditioning regimen (71% reduced BUCY 2) [11], 
which could have reduced tissue damage, one of the proposed 
mechanisms that initiate GVHD. Although patients receiving ATG as 
part of their conditioning regimen had a lower frequency of both 
acute and chronic GVHD, no statistical significant differences were 
observed.
There is only one retrospective case report published in 2015 [5] 
showing that oral administration of CsA could prevent the occurrence 
of aGVHD comparable to IV administration. The authors [5] included 
a small cohort (48 patients), and they found differences in CsA 
concentrations during week 2, which we did not observe in our practice. 
The authors also concluded that oral administration was economically 
advantageous which coincides with our observations. It is important 
to restrain costs while maximizing outcomes in developing countries. 
Since IV CsA was withdrawn from the Mexican market, its importation 
was not feasible nor affordable for our HSCT program; thus, oral CsA 
is currently preferred due to reduced costs and less invested time in 
nursing care.
In conclusion, although showing that oral instead of IV CsA for aGVHD 
prophylaxis is feasible and financial resources can be reduced in 
developing countries when IV formulation is not available, aGVHD 
incidence was higher in the oral CsA group. Thus, if possible, IV 
formulation should be used to further reduce GVHD in our patients. 
Despite including patients for almost two decades, none of our 
practices changed throughout the years; therefore, that is not a 
disadvantage for our results. Yet, we acknowledge that this study has 
limitations: It was performed retrospectively, including a reduced 
group of patients with IV CsA; therefore, further prospective studies 
are encouraged.
ACKNOWLEDGMENTS
We thank the non-governmental and non-profit organization “Unidos…
Asociacion Pro Trasplante de MedulaOsea,” in Mexico City, for 
facilitating most of our patients the acquisition of medications, and 
providing emotional support.
AUTHORS’ CONTRIBUTIONS
Analyzed the data: MMRF. Wrote the first draft of the manuscript: 
MMRF. Contributed to the writing of the manuscript: ELR. Agree with 
manuscript results and conclusions: All authors. Jointly developed 
the structure and arguments for the paper. All authors. Made critical 
revisions and approved final version: ELR. All authors reviewed and 
approved of the final manuscript.
CONFLICTS OF INTEREST 
None of the authors have conflicts of interest or competing financial 
interests.
REFERENCES
1. Ruutu T, van Biezen A, Hertenstein B, Henseler A, Garderet L, 
Passweg J, et al. Prophylaxis and treatment of GVHD after allogeneic 
haematopoietic SCT: A survey of centre strategies by the European 
group for blood and marrow transplantation. Bone Marrow Transplant 
2012;47:1459-64.
2. Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, 
Bacigalupo A, et al. Prophylaxis and treatment of GVHD: EBMT–ELN 
working group recommendations for a standardized practice. Bone 
Marrow Transplant 2014;49:168-73.
3. Oshima K, Kanda Y, Nakasone H, Arai S, Nishimoto N, Sato H, et al. 
Decreased incidence of acute graft-versus-host disease by continuous 
infusion of cyclosporine with a higher target blood level. Am J Hematol 
2008;83:226-32.
4. Izumi N, Furukawa T, Sato N, Okazuka K, Tsukada N, Abe T, et al. 
Risk factors for acute graft-versus-host disease after allogeneic 
hematopoietic stem cell transplantation: Retrospective analysis of 
73 patients who received cyclosporin A. Bone Marrow Transplant 
2007;40:875-80.
5. Nygaard M, Hovgaard D, Schjødt IM, Andersen NS, Vindeløv L, 
Sengeløv H, et al. Oral cyclosporine A treatment is feasible after 
myeloablative conditioning in allogeneic hematopoietic stem cell 
transplantation. J Clin Pharm Ther 2015;40:358-61.
6. Inoue Y, Saito T, Ogawa K, Nishio Y, Kosugi S, Suzuki Y, et al. 
Pharmacokinetics of cyclosporine a conversion from twice-daily 
infusion to oral administration in allogeneic hematopoietic stem cell 
transplantation. Am J Ther 2014;21:377-84.
7. Vigorito AC, Campregher PV, Storer BE, Carpenter PA, Moravec CK, 
Kiem HP, et al. Evaluation of NIH consensus criteria for classification 
of late acute and chronic GVHD. Blood 2009;114:702-8.
8. Ringdén O, Horowitz MM, Sondel P, Gale RP, Biggs JC, Champlin RE, 
et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host 
disease after HLA-identical sibling bone marrow transplants for early 
leukemia? Blood 1993;81:1094-101.
9. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, 
et al. National institutes of health consensus development project on 
criteria for clinical trials in chronic graft-versus-host disease: I. The 
2014 diagnosis and staging working group report. Biol Blood Marrow 
Transplant 2015;21:389-4010.
10. Rubio MT, Labopin M, Blaise D, Socié G, Contreras RR, Chevallier P, 
et al. The impact of graft-versus-host disease prophylaxis in reduced-
intensity conditioning allogeneic stem cell transplant in acute myeloid 
leukemia: A study from the acute leukemia working party of the 
European group for blood and marrow transplantation. Haematologica 
2015;100:683-9.
11. Leon Rodriguez E, Rivera Franco MM, Perez Alvarez SI. Reduced 
BUCY 2 and G-CSF-primed bone marrow associates with low graft-
versus-host-disease and transplant-related mortality in allogeneic 
HSCT. Ann Hematol 2017;96:1525-31.
111
 Leon-Rodriguez and Rivera-Franco 
Asian J Pharm Clin Res, Vol 11, Issue 12, 2018, 108-111
